Stocks · News reference

JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13

Sep 30, 2026, 5:55 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 30, 2026, 5:55 PM
Checked: Sep 30, 2026, 5:55 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 10, 2026, 2:57 PMBenzinga Newsdesk
BioCryst Pharma shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform rating and lowered its price target from $13 to $11.
BCRX
BenzingaSep 10, 2026, 2:37 PMBenzinga Newsdesk
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.
BCRX
BenzingaSep 8, 2026, 5:33 PMBenzinga Newsdesk
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target
BCRX